New EHA–ESMO Clinical Practice Guideline for primary CNS Lymphoma

ESMO shared a post on LinkedIn:         .

“New Primary Central Nervous System Lymphomas: European Hematology Association (EHA)–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Primary diffuse large B‐cell lymphoma (DLBCL) of the central nervous system (CNS), termed primary CNS Lymphoma, is an aggressive neoplasm presenting with disease limited to the CNS. This Clinical Practice Guideline covers clinical, imaging, and pathological diagnosis, staging and risk assessment, treatment, and algorithms for first-line and salvage treatments.”

Read further.
Source: ESMO/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information.

ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.